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1.1. 2,4-Diphenylthiazoles and 2,4-diphenyloxazoles as
potential novel prion disease therapeutics
Prion diseases, or transmissible spongiform encephalo-
pathies (TSEs), are invariably fatal neurodegenerative
disorders aﬀecting humans and animals. As yet, no eﬀective
curative or prophylactic therapy exists. Recent and
prominent examples of prion diseases include bovine
spongiform encephalopathy (BSE, in cattle) and scrapie
(in sheep). Since the discovery of a new variant of the
human TSE Creutzfeldt-Jacob disease (vCJD), prion
diseases have been brought into the focus of current
research. These diseases represent a highly signiﬁcant risk
to public health due to transmission both to and between
humans. Iatrogenic transmission has been reported via
contact with contaminated neurosurgical instruments for
example.
TSEs are associated with a post-translational conversion of
the cell-surface glycosylphosphatidylinositol-anchored pro-
tein PrPC (or PrPsen) to a partially protease resistant iso-
form denoted PrPSc (or PrPres). Recent work has
disclosed eﬀorts towards obtaining small drug-like mole-
cules that interact with human PrPC (huPrPC) and/or
reduce levels of PrPSc in persistently infected cells, with
the aim of identifying novel prion disease therapeutics. A
vHTS study followed by the screening of sourced com-
pounds by surface plasmon resonance (SPR) led to the
identiﬁcation of structure (1) as binding to huPrPC.1
Further, 5-aminooxazole derivative (2) also showed bind-
ing to huPrPC. In following up these results, these workers
designed a synthetic route to allow access to a library of
amide derivatives at the 5-position of aminothiazoles and
5-aminooxazoles through derivatisation of the free 5-
amino compound, depicted in generic chemotype (3).doi:10.1016/j.comche.2008.02.001
E-mail: nterrett@ensemblediscovery.comA solution phase library of 18 compounds was synthesised
as singletons based on the 5-aminothiazole template (3,
X=S), and 20 compounds based on the 5-aminooxazole
template (3, X=O). Compounds synthesised were screened
with SPR using a BIAcore 3000 instrument equipped with
a CM5 (carboxymethylated dextran) sensor chip. Interac-
tions were measured with two forms of prion protein, full
length huPrPC and full length murine PrPC (moPrPC).
Binding aﬃnities are expressed as %RUmax: a percentage
of the theoretical maximum response for 1:1 protein-ligand
binding. Compounds were also screened for inhibition of
PrPSc formation in scrapie murine brain (SMB) cells of
mesodermal origin.From these libraries, several binders to huPrPc and moPrPc
were obtained. One of the compounds with the highest
binding aﬃnity was 4 which possessed a RUmax of 48%
for huPrPc. Although it was not possible to establish any
direct correlation between PrPC binding aﬃnity and cell
line activity from this work, it is encouraging to note that
all of the active compounds showed binding to the full-
length human PrPC, and all but one to the murine protein.
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compounds exempliﬁed by the chemotype 3.
1.2. Inhibitors of protein kinase B using fragment-based lead
discovery
The serine/threonine kinase protein kinase B (PKB or Akt)
plays a central role in the regulation of a variety of signal
transduction pathways necessary for the control of cell
growth, diﬀerentiation, and division. Overexpression and
disregulation of PKB has been demonstrated in a number
of human malignancies, thus giving a potential mechanism
for the survival and progression of tumour cells. Thus,
inhibition of PKB is considered to be a potentially valuable
approach to the treatment of cancers. One of the most fre-
quently applied strategies for inhibiting PKB is targeting of
the kinase domain by competitive inhibition of the ATP
binding site.
The recent availability of the three-dimensional crystal
structure of active, phosphorylated PKB (Akt-2) has pro-
vided further opportunities for the development of novel
ATP-competitive inhibitors. Its application however to
iterative structure-based design has so far been limited by
the lack of a robust, soakable crystal form. Methodol-
ogy and technology to aid in the production of x-ray crys-
tal structures with small molecule inhibitors would
therefore be of value. Recent work has disclosed the suc-
cessful application of x-ray crystallography for the rapid
development of a potent series of ATP competitive PKB
inhibitors.2
Fragment screening was carried out using the ‘Pyramid’
approach. This approach identiﬁed fragment 5 as an x-
ray hit when it was soaked into crystals of a PKA-PKB chi-
mera. Inspection of how the fragment binds suggested
ideas for elaboration of the inhibitor, allowing a concomi-
tant increase in potency. Several iterative rounds of com-
pound synthesis, biological testing, soaking and x-ray
analysis of PKA-PKB followed by inhibitor inspection
and further design led to a number of potent inhibitors
of PKB. One of the most potent was 6 which possessed
an IC50 against PKB of 18nM. The use of fragment-based
drug discovery facilitated the rapid identiﬁcation of novel,
low molecular weight PKB/Akt inhibitors. By applying
protein-ligand crystallography to iterative rounds of
structure based design, elaboration of the initial hit was
successfully carried out to provide nanomolar PKB
inhibitors.HN N
NH
HN N
Cl
5
PKB IC50 = 80 μM
      6
PKB IC50 = 18 nM2. A summary of the papers in this month’s issue
2.1. Solid-phase synthesis
No papers this month.
2.2. Solution-phase synthesis
Pyridinium chlorochromate (PCC) supported on silica gel
allows the oxidative cyclisation of structurally diverse thio-
phenolic and phenolic Schiﬀ’s bases, thereby providing an
eﬃcient and convenient method for the synthesis of a
library of 2-arylbenzothiazoles and 2-arylbenzoxazoles.3
2.3. Scaﬀolds for combinatorial libraries
The stereoselective synthesis of aminooxy-containing pro-
line analogues bearing Fmoc/Boc or Fmoc/Mtt protection,
that renders them suitable for incorporation into peptides
using Fmoc protocols, has been reported. Acid-catalysed
unmasking at the completion of peptide synthesis yields
free aminooxy-functionalities for oxime formation through
reaction with libraries of aldehydes. This allows post solid-
phase diversiﬁcation strategies that may facilitate struc-
ture–activity relationship studies.4
2.4. Solid-phase supported reagents
Merriﬁeld resin-supported cinchona ammonium salts bear-
ing 20-ﬂuorobenzene, 20-cyanobenzene and 20-N-oxypyr-
idine groups have been prepared. These have been
applied to the phase-transfer catalytic alkylation of
N-(diphenylmethylene)glycine tert-butyl ester for the
enantioselective synthesis of a-amino acids in 76–96% e.e.5
An eﬃcient and solvent-free synthesis of O-alkyl hydrogen
alkyl phosphonates has been described. The methodology
involves the condensation of alkyl phosphonic acids using
DCC–Celite under solvent-free conditions.6
2.5. Novel resins, linkers and techniques
No papers this month.
2.6. Library applications
A novel one-pot synthesis of 2,4-substituted 5-azolylthio-
pyrimidines has been achieved by sequential Michael-addi-
tion of 3-iodochromones with mercaptoazole (or
mercaptotriazoles) and then condensation with a variety
of amidines. One reported compound exhibited potent
anti-inﬂuenza virus A activity with an IC50 value of 21.56
mg/mL and an SI value of 9.7
A small library of simple 1,4-disubstituted 1,2,3-triazoles
has been prepared using a known one-pot procedure start-
ing from organic halides and terminal alkynes. The com-
pounds were tested for their antibacterial activity against
normal and resistant species of Staphylococcus aureus.8
Two approaches for the design of constrained and uncon-
strained peptides in an investigation of the peptide binding
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tigated. Based on the modelling of an active peptide back-
bone in the active site of HMGR, two hypocholesterolemic
peptide libraries for constrained and unconstrained pep-
tides were designed using diﬀerent amino acids varying in
hydrophobicity and electronic properties.9
A new synthetic route to pyridopyrimidines to facilitate their
structural optimisation through a library has been described.
These pyridopyrimidines have excellent enzymatic and cell
potency against Akt1 and Akt2, and also show a high level
of selectivity over other closely related kinases.10
Based on the concept that cationic charge, bulk and lipo-
philicity are major factors determining antibacterial activ-
ity of peptides, several combinatorial libraries based on
1,3,5-triazine as a template have been designed and
screened. A set of compounds were identiﬁed that show po-
tent antimicrobial activity together with low haemolytic
activity.11
A diversity-oriented synthesis approach has been devel-
oped for facile construction of a library of carbohydrate–
cyclopamine conjugates. From this initial library, one
derivative that exhibits improved activity against lung can-
cer cells as compared to cyclopamine has been observed.12
Diverse substituted 2-pyrrolines have been prepared by a
novel multicomponent process involving a reaction of var-
ious N-(aryl- and alkylsulphonamido)-acetophenones with
aldehydes and malononitrile. A number of analogues from
both cis and trans 2-pyrroline libraries were found to have
antiproliferative activity in human cancer cell lines.13
A series of OX2R/OX1R dual orexin antagonists has been
prepared based on a proline bis-amide identiﬁed as a
screening lead. Through a combination of classical and li-
brary synthesis, potency enhancing replacements for both
amide portions were discovered. A compound from this
series has demonstrated in vivo central activity when dosed
peripherally in a pharmacodynamic model of orexin
activity.14
A parallel synthesis of aryl azoles with neuroprotective
activity has been described. All compounds obtained were
evaluated in an in vitro assay using a NMDA toxicity par-
adigm and showed a neuroprotective activity between 15%
and 40%.15
The synthesis and SAR, developed through an iterative
analogue library approach, of a novel series of selective
M1 mAChR antagonists for the potential treatment of Par-
kinson’s disease, dystonia and other movement disorders
has been reported. Compounds in this series possess M1
antagonist IC50 values in the 441 nM—19 lM range with
8- to >340-fold functional selectivity versus rM2–rM5
receptors.16
Employing D4 selective azaindoles as lead compounds, a
focussed library of carbocyclic arene bioisosteres has been
synthesised using a click chemistry-derived triazolylmethyl
acrylate resin. Ligand binding assays on monoaminergicGPCRs led to SARs that indicated further lead structure
optimisation. The attachment of alkoxy substituents pro-
vided both an improvement of the biological properties
and the opportunity to introduce 18F as a radioisotope.
One compound represented a promising dopamine D4
selective radioligand for positron emission tomography.17
The optimisation of previously described hydroxy ethyl-
amine (HEA) BACE-1 inhibitors obtained from a focussed
library with the support of X-ray crystallography has been
described. Optimisation of the non-prime side of the inhi-
bitors and introduction of a 6-membered sultam substi-
tuent binding to Asn-294, as well as a ﬂuorine in the C-2
position, led to derivatives with nanomolar potency in
cell-based assays.18References
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